| scholarly article | Q13442814 |
| P2093 | author name string | Molly E Steed | |
| Nicholas S Britt | |||
| Nimish Patel | |||
| Rebecca T Horvat | |||
| P2860 | cites work | Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia | Q21261829 |
| Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function | Q33883752 | ||
| High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis | Q34454418 | ||
| Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates | Q34529085 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients | Q34991274 | ||
| Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia | Q35879117 | ||
| Predictors of mortality in Staphylococcus aureus Bacteremia | Q35940556 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q37623755 | ||
| Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? | Q38039908 | ||
| Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression | Q38052237 | ||
| In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. | Q38367748 | ||
| Oxacillin, cephalothin, and vancomycin tube macrodilution MBC result reproducibility and equivalence to MIC results for methicillin-susceptible and reputedly tolerant Staphylococcus aureus isolates | Q39817823 | ||
| Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models | Q41249548 | ||
| Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations | Q41249846 | ||
| Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals | Q41299360 | ||
| Vancomycin tolerance in methicillin-resistant Staphylococcus aureus: influence of vancomycin, daptomycin, and telavancin on differential resistance gene expression | Q42280738 | ||
| Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia | Q42706371 | ||
| Inhibition of the autolytic system by vancomycin causes mimicry of vancomycin-intermediate Staphylococcus aureus-type resistance, cell concentration dependence of the MIC, and antibiotic tolerance in vancomycin-susceptible S. aureus | Q43203250 | ||
| Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals | Q43278332 | ||
| Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin . | Q44847000 | ||
| Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? | Q45394930 | ||
| Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? | Q46759948 | ||
| Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. | Q46879391 | ||
| Vancomycin: we can't get there from here. | Q51608468 | ||
| Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. | Q54062872 | ||
| Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets | Q83770914 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 3070-3075 | |
| P577 | publication date | 2016-03-07 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia | |
| P478 | volume | 60 |
Search more.